GuideInfectious diseases
COVID-19 vaccine effectiveness against the Delta variant (and current vaccine recommendation)
Summarises the 2021 English study on vaccine protection against Delta and the current CDC vaccination recommendation.
Updated 3 November 2026
When to use it
As historical context on variants and full-course vaccination, and to check who is currently recommended to be vaccinated.
Warning
The Delta variant no longer circulates and the vaccines studied have been replaced by updated formulations: the study is of historical value. The vaccine recommendation summarised is the CDC one as of 23 September 2026.
The study
Lopez Bernal et al. (NEJM, 2021) used a test-negative case–control design including all sequenced symptomatic cases in England while Delta (B.1.617.2) was replacing Alpha (B.1.1.7). They assessed the BNT162b2 (Pfizer-BioNTech) and ChAdOx1 nCoV-19 (AstraZeneca) vaccines.
Keep reading in the app
- Results (against symptomatic COVID-19)
- Current recommendation (CDC, 2026–2027 season)
- Limitations
Practical tip
Main lesson from the study: a single dose gave little protection against Delta; the full course restored most of the protection.
2 more practical tips in the app.
Reference
- Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021;385(7):585-594.
- Centers for Disease Control and Prevention. 2026-2027 COVID-19 Vaccination Guidance for People Who Are Not Immunocompromised (updated 23 Sep 2026).
Official source: CDC: 2026–2027 COVID-19 vaccination guidance
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
